Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03301519
Other study ID # HS 013025
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2001
Est. completion date May 31, 2013

Study information

Verified date November 2023
Source University of Southern California
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a family based genotype-phenotype study designed to assess genetic and environmental influences on obesity, insulin resistance and beta cell function in the context of gestational diabetes.


Description:

Mexican American women with prior gestational diabetes and their first degree relatives and Mexican American women with prior normal glucose tolerance in pregnancy are studied with detailed phenotyping consisting of oral and intravenous glucose tolerance tests, body composition studies, diet and physical activity assessments, and circulating biomarkers potentially related to obesity, insulin resistance, pancreatic beta cell function, gestational diabetes and type 2 diabetes. Spouses of the gestational diabetic and control probands are studied with oral glucose tolerance tests. Offspring of the gestational and control probands have fasting glucose determinations. All participants provide DNA for genetics testing. A subset of the gestational diabetic probands and their first degree relatives return 3-5 years after baseline testing for repeat phenotyping.


Recruitment information / eligibility

Status Completed
Enrollment 1250
Est. completion date May 31, 2013
Est. primary completion date May 31, 2013
Accepts healthy volunteers No
Gender All
Age group 8 Years and older
Eligibility INCLUSION CRITERIA 1. Probands with Prior Gestational Diabetes Mellitus ("GDM PROBANDS") - Mexican American (parents and at least 3/4 four grandparents - age >18 years - GDM in singleton pregnancy in prior 5 years - impaired glucose levels or sum of five OGTT glucose values >625 mg/dl on 75 gram oral glucose tolerance test - Fasting plasma glucose <126 mg/dl - At least two adult siblings of cousin not known to have diabetes and available for phenotyping; . 2. Siblings and Cousins of GDM Probands - Full sibling or first cousin of GDM proband - Age >18 yrs - Fasting plasma glucose <126 mg/dl. 3. Parents, Uncles and Aunts of GDM Probands - Full blooded parent, uncle or aunt of GDM proband 4. Control Proband - Mexican American as defined for GDM probands - One glucose challenge test result <120 mg/dl at >24 weeks gestation - No diabetes in first degree relative - Frequency matched to GDM probands by distributions of age, BMI and parity. 5. Spouse of GDM or Control Proband - Spouse of GDM proband - Age >18 - At least one child with proband able to provide DNA 6. Child of Proband - Child of GDM or control proband and spouse who provided DNA EXCLUSION CRITERIA 1. PROBANDS (GDM OR CONTROL): - Chronic medical illness or medication known to alter glucose/insulin metabolism - Current pregnancy or breastfeeding - Ilicit drug or alcohol abuse, - Inability or unwillingness to give informed consent. 2. SIBLINGS AND COUSINS OF PROBANDS: - Chronic medical illness or medication known to affect glucose/insulin metabolism - Current pregnancy or breastfeeding, - Ilicit drug or alcohol abuse - Inability or unwillingness to give informed consent. 3. PARENTS OF PROBANDS - Inability or unwillingness to give informed consent. 4. SPOUSE OF GDM or CONTROL PROBAND - Inability or unwillingness to give informed consent. 5. CHILD OF GDM or CONTROL PROBAND - Lack of parent consent or child assent.

Study Design


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Southern California Kaiser Permanente

Outcome

Type Measure Description Time frame Safety issue
Primary Pancreatic Beta Cell Compensation for Insulin Resistance Disposition index from intravenous glucose tolerance test Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Insulin Senstivity Si from computer modeled intravenous glucose tolerance test Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Acute Insulin Release Incremental area under insulin curve during first 10 minutes intravenous glucose tolerance test Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Glucose tolerance normal, impaired or diabetic glucose level determined using American Diabetes Associate criteria applied to glucose levels from a 2-hour, 75 gram oral glucose tolerance test Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Diabetes type 2 Fasting glucose >125 mg/dl and/or 2-hour glucose on 75 gram oral glucose tolerance test >199 mg/dl Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Dietary Intake Measured by semi-quantitative Harvard Food Frequency Questionnaire Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Physical Activity Measured by Multi-ethnic Cohort Physical Activity Questionnaire Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Body Fat Percent body fat measured by dual photon X-ray absorptiometry Single time point for primary cohort, repeated 4.5 years later in subset
Secondary Circulating adipokine levels Fasting levels of approximately 20 adipocytokines Single time point for primary cohort, repeated 4.5 years later in subset
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2